RLF

Relief Hldg Stock

StockStock
ISIN: CH1251125998
Ticker: RLF
CH1251125998
RLF

Price

Frequently asked questions

What is Relief Hldg's market capitalization?

The market capitalization of Relief Hldg is $105.42M. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.

What is the Earnings Per Share (EPS) for Relief Hldg?

Relief Hldg's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$4.217. EPS indicates the company's profitability on a per-share basis.

What is Relief Hldg's revenue over the trailing twelve months?

Over the trailing twelve months, Relief Hldg reported a revenue of $9.74M.

What is the EBITDA for Relief Hldg?

Relief Hldg's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$10.17M. EBITDA measures the company's overall financial performance.

What is the free cash flow of Relief Hldg?

Relief Hldg has a free cash flow of -$11.88M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.

How many employees does Relief Hldg have, and what sector and industry does it belong to?

Relief Hldg employs approximately 36 people. It operates in the Health Care sector, specifically within the Biotechnology & Drugs industry.

What is the free float of Relief Hldg's shares?

The free float of Relief Hldg is 9.65M. Free float refers to the number of shares available for public trading, excluding restricted shares.

Financials

Market Cap

 
$105.42M

EPS (TTM)

 
-$4.217

Free Float

 
9.65M

Revenue (TTM)

 
$9.74M

EBITDA (TTM)

 
-$10.17M

Free Cashflow (TTM)

 
-$11.88M

Information

RELIEF THERAPEUTICS Holding SA is a Switzerland-based biopharmaceutical company. The Company’s objective is to provide patients with therapeutic relief in serious diseases with high unmet medical need, as well as to focus on developing treatments for respiratory diseases. It specializes in clinical-stage projects based on molecules of natural origin (peptides and proteins with a history of clinical use and either initial human activity with efficacy data or a strong scientific rationale. Its lead compound is RLF-100 (aviptadil), a synthetic human vasoactive intestinal peptide (VIP) with a multifaceted mode of action in respiratory indications. RLF-100 is being investigated in two placebo-controlled U.S. phase 2b/3 clinical trials in respiratory deficiency due to COVID-19. Its RLF-100 is also used for pulmonary sarcoidosis. The Company is also involved in the clinical development of RLF-100 that is in planning stage for other indications in acute and chronic lung diseases.

36

Biotechnology & Drugs

Health Care

Identifier

ISIN

CH1251125998

Primary Ticker

RLF
Join the conversation